APTAMIR
Live / Applied — Second extension granted (statement of use) (as of 29 Jan 2026)
What this means for you
Not registered yet, but its 10 Apr 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97880127
- Mark type
- Design + words
- Filed
- 10 Apr 2023
- Published for opposition
- 28 Jan 2025
- Attorney of record
- Linda M. Merritt
Goods and services
- Class 005 — Pharmaceuticals: Medicinal and biological preparations for pharmaceutical, clinical and medical treatment, namely, preparations for the modulation of gene and protein expression working at DNA transcription, RNA translation and degradation processes related thereto for the treatment of cardiovascular diseases, metabolic diseases, overweight, obesity, diabetes mellitus, dyslipidemia, liver steatosis, steatohepatitis, non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, atherosclerosis, chronic visceral inflammation, ovarian cancer and related diseases and disorders.
Owner
- AptamiR Therapeutics, Inc, Naples, FL, US
- AptamiR Therapeutics, Inc, Naples, FL, US
Prosecution history
- 29 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Jan 2026 — SOU EXTENSION 2 GRANTED
- 28 Jan 2026 — SOU EXTENSION 2 FILED
- 28 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 18 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Sept 2025 — SOU EXTENSION 1 GRANTED
- 17 Sept 2025 — SOU EXTENSION 1 FILED
- 17 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Jan 2025 — PUBLISHED FOR OPPOSITION
- 22 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 01 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE